Skip to main content
Signal8

Evogene Reports First Quarter 2026 Financial Results

$EVGNPress releaseMay 20, 2026, 7:00 AM ETRead the release

Evogene reported Q1 2026 revenue of $0.3 million, a significant decline from $2.3 million in the prior year, driven by the wind-down of non-core subsidiaries like Casterra. The company posted a net loss of $5.9 million, widening from $3.0 million year-over-year, largely due to decreased revenues and increased financing expenses related to warrant revaluations.

Key figures

Revenue
334000
Revenue Yoy
-86%
Net loss
5896000
Operating loss
3150000
R and d expense
1839000
Warrant liability
1721000
Shares outstanding
10412764
Financing expense net
2713000

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.